Globally, Acinetobacter baumannii has emerged as an important nosocomial pathogen and as highly resistant to clinically relevant antibiotics, namely, carbapenems. In this study, we aimed to determine the epidemiological profile and the imipenem (IPM) resistance rate of a clinical collection of A. baumannii isolates. This study was carried out at the Central Laboratory of the Oran Regional University Military Hospital (Hôpital militaire régional universitaire d’Oran) over a period of 7 years (January 2010–December 2016). The frequency of A. baumannii isolates was not constant over the 7 years; however, an increasing trend was observed. Among the 168 isolates, the majority was isolated from male patients (n = 131, 78%). Patients in the intensive care unit had a higher risk of developing A. baumannii infection (76%) compared to other hospital services, and protected distal pulmonary samples were the main site of isolation of A. baumannii isolates (34%). Among the collected isolates, 106 were IPM resistant and exhibited multidrug phenotypes. These results confirm the multidrug-resistant nature of A. baumannii and its nosocomial behavior. The emergence of this bacterial species represents a serious therapeutic and epidemiological problem, hence the need for the establishment of a system for monitoring the microbial environment of the hospital and the strict application of hygiene measures.
AlmasaudiSB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J Biol Sci, 2018; 25(3):586–596; doi: 10.1016/j.sjbs.2016.02.009
2.
LucidiM, VisaggioD, MigliaccioA, et al.Pathogenicity and virulence of Acinetobacter baumannii: Factors contributing to the fitness in healthcare settings and the infected host. Virulence, 2024; 15(1):2289769; doi: 10.1080/21505594.2023.2289769
3.
MeaHJ, YongPVC, WongEH. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiol Res, 2021; 247:126722; doi: 10.1016/j.micres.2021.126722
4.
HardingCM, HennonSW, FeldmanMF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol, 2018; 16(2):91–102; doi: 10.1038/nrmicro.2017.148
5.
MonemS, Furmanek-BlaszkB, ŁupkowskaA, et al.Mechanisms protecting Acinetobacter baumannii against multiple stresses triggered by the host immune response, antibiotics and outside-host environment. Int J Mol Sci, 2020; 21(15):5498; doi: 10.3390/ijms21155498
6.
DijkshoornL, NemecA, SeifertH. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, 2007; 5(12):939–951; doi: 10.1038/nrmicro1789
7.
ZarrilliR. Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. Virulence, 2016; 7(4):367–368; doi: 10.1080/21505594.2016.1150405
8.
EzeEC, CheniaHY, El ZowalatyME. Acinetobacter baumannii biofilms: Effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist, 2018; 11:2277–2299; doi: 10.2147/IDR.S169894
9.
WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Sept 4, 2017. Available from: https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 [Last accessed: June, 2025].
10.
LeeCR, LeeJH, ParkM, et al.Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol, 2017; 7:55; doi: 10.3389/fcimb.2017.00055
11.
LeeK, YongD, JeongSH, et al.Multidrug-resistant Acinetobacter spp: Increasingly problematic nosocomial pathogens. Yonsei Med J, 2011; 52(6):879–891; doi: 10.3349/ymj.2011.52.6.879
12.
NguyenM, JoshiSG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: A scientific review. J Appl Microbiol, 2021; 131(6):2715–2738; doi: 10.1111/jam.15130
13.
MüllerC, ReuterS, WilleJ, et al.A global view on carbapenem-resistant Acinetobacter baumannii. mBio, 2023; 14(6):e0226023; doi: 10.1128/mbio.02260-23
14.
RamirezMS, BonomoRA, TolmaskyME. Carbapenemases: Transforming Acinetobacter baumannii into a yet more dangerous menace. Biomolecules, 2020; 10(5):720; doi: 10.3390/biom10050720
15.
NowakP, PaluchowskaP. Acinetobacter baumannii: Biology and drug resistance - role of carbapenemases. Folia Histochem Cytobiol, 2016; 54(2):61–74; doi: 10.5603/FHC.a2016.0009
16.
HuangL, SunL, XuG, et al.Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital. Diagn Microbiol Infect Dis, 2008; 62(3):326–332; doi: 10.1016/j.diagmicrobio.2008.06.008
17.
RaddaouiA, MabroukA, ChebbiY, et al.Co-occurrence of blaNDM-1 and blaOXA-23 in carbapenemase-producing Acinetobacter baumannii belonging to high-risk lineages isolated from burn patients in Tunisia. J Appl Microbiol, 2024; 135(3):lxae039; doi: 10.1093/jambio/lxae039
18.
Badger-EmekaLI, EmekaPM, QuadriSA. Periodic phenotypic profile analysis of Acinetobacter baumannii drug resistance characteristics showing the emergence of PDR. Eur Rev Med Pharmacol Sci, 2024; 28(19):4383–4401; doi: 10.26355/eurrev_202410_36834
19.
TouatiA, AchourW, CherifA, et al.Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: Antimicrobial susceptibility and genotyping analysis. Ann Epidemiol, 2009; 19(6):372–378; doi: 10.1016/j.annepidem.2009.03.010
20.
RamoulA, LoucifL, BakourS, et al.Co-occurrence of blaNDM-1 with blaOXA-23 or blaOXA-58 in clinical multidrug-resistant Acinetobacter baumannii isolates in Algeria. J Glob Antimicrob Resist, 2016; 6:136–141; doi: 10.1016/j.jgar.2016.05.003
21.
BenamroucheN, LaferO, BenmahdiL, et al.Phenotypic and genotypic characterization of multidrug-resistant Acinetobacter baumannii isolated in Algerian hospitals. J Infect Dev Ctries, 2020; 14(12):1395–1401; doi: 10.3855/jidc.12348
22.
LabidA, BenouagueniS, MehainaouiA, et al.Antimicrobial resistance among Gram-negative bacteria isolated in the newborn intensive care unit at Abderrezak-Bouhara hospital of Skikda, Algeria. Microb Drug Resist, 2023; 29(6):229–238; doi: 10.1089/mdr.2022.0254
23.
ZenatiK, TouatiA, BakourS, et al.Characterization of NDM-1- and OXA-23-producing Acinetobacter baumannii isolates from inanimate surfaces in a hospital environment in Algeria. J Hosp Infect, 2016; 92(1):19–26; doi: 10.1016/j.jhin.2015.09.020
24.
YagoubatM, Ould El-Hadj-KhelilA, MalkiA, et al.Genetic characterisation of carbapenem-resistant Gram-negative bacteria isolated from the University Hospital Mohamed Boudiaf in Ouargla, southern Algeria. J Glob Antimicrob Resist, 2017; 8:55–59; doi: 10.1016/j.jgar.2016.10.008
25.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Wayne, PA: CLSI; 2010 Document M100-S20.
26.
MagiorakosAP, SrinivasanA, CareyRB, et al.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012; 18(3):268–281; doi: 10.1111/j.1469-0691.2011.03570.x
27.
BoualiA, BendjamaE, CherakZ, et al.Distribution of carbapenemase-producing and colistin resistant Acinetobacter baumannii isolates in Batna hospitals, Algeria. BMC Infect Dis, 2025; 25(1):825; doi: 10.1186/s12879-025-11198-6
28.
TouatiM, DieneSM, RacheracheA, et al.Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria. Int J Antimicrob Agents, 2012; 40(1):89–91; doi: 10.1016/j.ijantimicag.2012.03.017
29.
BoudiaM. Etude multicentrique de la résistance aux antibiotiques chez Acinetobacter baumannii. Thèse de Biochimie Appliquée. Abou BekrBelkaid (Tlemcen) 2014.p 94.
30.
KhaldiH. Epidémiologie de l’infection à Acinetobacter baumannii au CHU de Marrakech. Thèse de Médecine. CADI AYYAD (Marrakech) 2016. N°146: p 97.
31.
RajilD. Acinetobacter baumanii: Épidémiologie et résistance aux antibiotiques. Thèse de Médecine. MARRAKECH (Maroc) 2019. N°102: pp. 13–17.
32.
MusyokiVM, MasikaMM, MutaiW, et al.Antimicrobial susceptibility pattern of Acinetobacter isolates from patients in Kenyatta National Hospital, Nairobi, Kenya. Pan Afr Med J, 2019; 33:146; doi: 10.11604/pamj.2019.33.146.17220
33.
WielandK, ChhatwalP, VonbergRP. Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa: Results of a systematic review. Am J Infect Control, 2018; 46(6):643–648; doi: 10.1016/j.ajic.2017.12.014
34.
SoukainaW. Epidémiologie et résistance aux antibiotiques des isolats cliniques d’Acinetobacter baumannii à l’hôpital militaire moulay Ismail—Meknés. Thèse de Medecine. Sidi mohammed Ben abdellah (Royaume de Maroc) 2017. N° 85: pp. 30–40.
35.
VillarM, CanoME, GatoE, et al.; GEIHGEMARAREIPI-Ab20101 Group. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: A reappraisal. Medicine (Baltimore), 2014; 93(5):202–210; doi: 10.1097/MD.0000000000000036
36.
García-GarmendiaJL, Ortiz-LeybaC, Garnacho-MonteroJ, et al.Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: A cohort study. Clin Infect Dis, 2001; 33(7):939–946; doi: 10.1086/322584
37.
DraultJN, HerblandA, KaidomarS, et al.Pneumopathie communautaire à Acinetobacter Baumannii [Community-acquired Acinetobacter baumannii pneumonia]. Ann Fr Anesth Reanim, 2001; 20(9):795–798; doi: 10.1016/S0750-7658(01)00497-X
38.
MerzouguiL, BarhoumiT, GuizaniT, et al.Les infections nosocomiales en milieu de réanimation: Incidence annuelle et aspects cliniques au service de réanimation polyvalente, Kairouan, Tunisie 2014. Pan Afr Med J, 2018; 30:143. French; doi: 10.11604/pamj.2018.30.143.13824
39.
JiangY, DingY, WeiY, et al.Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit. Front Microbiol, 2022; 13:1045206; doi: 10.3389/fmicb.2022.1045206
40.
WongD, NielsenTB, BonomoRA, et al.Clinical and pathophysiological overview of Acinetobacter Infections: A century of challenges. Clin Microbiol Rev, 2017; 30(1):409–447; doi: 10.1128/CMR.00058-16
41.
ThacharodiA, VithlaniA, HassanS, et al.Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience, 2024; 27(12):111367; doi: 10.1016/j.isci.2024.111367
42.
CorvecS, PoirelL, NaasT, et al.Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother, 2007; 51(4):1530–1533; doi: 10.1128/AAC.01132-06
43.
DjahmiN, Dunyach-RemyC, PantelA, et al.Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int, 2014; 2014:305784; doi: 10.1155/2014/305784
44.
SekyereJO, GovindenU, EssackS. The molecular epidemiology and genetic environment of carbapenemases detected in Africa. Microb Drug Resist, 2016; 22(1):59–68; doi: 10.1089/mdr.2015.0053
45.
WardhanaA, DjanR, HalimZ. Bacterial and antimicrobial susceptibility profile and the prevalence of sepsis among burn patients at the burn unit of Cipto Mangunkusumo Hospital. Ann Burns Fire Disasters, 2017; 30(2):107–115.
46.
QuJ, ZouJ, ZhangJ, QuJ, LuH. Phage therapy for extensively drug resistant Acinetobacter baumannii infection: Case report and in vivo evaluation of the distribution of phage and the impact on gut microbiome. Front Med (Lausanne), 2024; 11:1432703.
47.
AlexanderPJ, OyamaLB, OlleikH, et al.Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii. NPJ Biofilms Microbiomes, 2024; 10(1):92.
48.
HuangD, ZengZ, LiZ, et al.Sequential immune acquisition of monoclonal antibodies enhances phagocytosis of Acinetobacter baumannii by recognizing ATP synthase. Vaccines (Basel), 2024; 12(10):1120.
49.
AlumEU, GulumbeBH, IzahSC, et al.Natural product-based inhibitors of quorum sensing: A novel approach to combat antibiotic resistance. Biochem Biophys Rep, 2025; 43:102111.
50.
AllendSO, Oliveira GarciaM, da CunhaKF, et al.The synergic and addictive activity of biogenic silver nanoparticle associated with meropenem against carbapenem-resistant Acinetobacter baumannii. J Appl Microbiol, 2024; 135(3):lxae046.
51.
El FannassiY, GharsallaouiA, KhelissaS, et al.Complexation of terpenes for the production of new antimicrobial and antibiofilm molecules and their encapsulation in order to improve their activities. Appl Sciences, 2023; 13(17):985.
52.
PaneriM, SevtaP, YagnikVD. Efficacy of plant extracts against carbapenem resistant Acinetobacter baumannii: A notorious pathogen in the intensive care unit. GJMPBU, 2023; 18:24.
53.
KnezevicP, AleksicV, SiminN, et al.Antimicrobial activity of Eucalyptus camaldulensis essential oils and their interactions with conventional antimicrobial agents against multi-drug resistant Acinetobacter baumannii. J Ethnopharmacol, 2016; 178:125–136.
54.
TiwariM, RoyR, TiwariV. Screening of herbal-based bioactive extract against carbapenem-resistant strain of Acinetobacter baumannii. Microb Drug Resist, 2016; 22(5):364–371.
